2022

Abstract blue cross shape with flowing dark teal wave lines on a solid black background.
Abstract soft light blue gradient glow on a solid white background.
11 • 17 • 2022
NervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade Office
11 • 15 • 2022
NervGen Pharma Grants Stock Options
11 • 14 • 2022
NervGen Pharma Completes Dosing in its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results
10 • 31 • 2022
NervGen Engages Cloutier Consulting to Provide Media Relations Services
10 • 25 • 2022
NervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen’s NVG-291
10 • 20 • 2022
NervGen Pharma Presenting at Upcoming Scientific Meetings
10 • 12 • 2022
NervGen Pharma Awarded up to $1.5 Million US Department of Defense Funding to Evaluate NervGen’s NVG-291-R for Peripheral Nerve Injury
09 • 29 • 2022
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
09 • 22 • 2022
NervGen Pharma Announces Leadership Transition
1 2 3 4